Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis Against OHSS in PCOS Women
NCT06739759Recruiting
- Sponsor
- Al Jazeera Hospital
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in ovarian hyperstimulation syndrome (OHSS) (2 arms), sponsored by Al Jazeera Hospital. Primary endpoint: prevention of OHSS at 3 weeks. Started Nov 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on NCT06739759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739759.